Ascendis Pharma A (ASND) Operating Margin (2014 - 2026)
Ascendis Pharma A (ASND) reported Operating Margin of 10.06% for Q1 2026, up 11329.0% on a YoY basis from N/an in Q1 2025, and up 323.42% sequentially from 2.38% in Q4 2025.
Ascendis Pharma A (ASND) Operating Margin (2014 - 2026) Analysis & Trends
Ascendis Pharma A (ASND) has 13 years of Operating Margin data on file, last reported at 10.06% in Q1 2026.
- For the quarter ending Q1 2026, Operating Margin rose 11329.0% year-over-year to 10.06%; the trailing twelve-month figure through Mar 2026 stood at 0.54% (down 7576475.0% YoY), and the FY2025 full-year result was 18.92%, up 4978.0% from the prior year.
- Operating Margin improved to 10.06% in Q1 2026, from 2.38% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 123555.16% in Q4 2024 to a low of 2303.46% in Q2 2022.
- A 5-year average of 6827.24% and a median of 167.28% in 2024 frame the typical range for Operating Margin.
- Across the five-year window, Operating Margin surged 12356726 bps in 2024 and slumped 12355279 bps in 2025, its largest moves.
- Tracing ASND's Operating Margin over 5 years: stood at 643.75% in 2022, then soared by 98 bps to 12.09% in 2023, then surged by 1021723 bps to 123555.16% in 2024, then slumped by 100 bps to 2.38% in 2025, then surged by 323 bps to 10.06% in 2026.
- Business Quant data shows ASND's Operating Margin at 10.06% in Q1 2026, 2.38% in Q4 2025, and 5.15% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 16.51% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 30.35% |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Ascendis Pharma A | 15.35 Bn | 14.68 Bn | 268.20 Mn | 10.06% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.06% |
| Dec 31, 2025 | 2.38% |
| Sep 30, 2025 | 5.15% |
| Jun 30, 2025 | -33.50% |
| Mar 31, 2025 | -103.23% |
| Dec 31, 2024 | 123,555.16% |
| Sep 30, 2024 | -167.28% |
| Jun 30, 2024 | -370.18% |
| Mar 31, 2024 | -51.25% |
| Dec 31, 2023 | -12.09% |
| Sep 30, 2023 | -279.82% |
| Jun 30, 2023 | -297.17% |
| Mar 31, 2023 | -427.77% |
| Dec 31, 2022 | -643.75% |
| Sep 30, 2022 | -945.09% |
| Jun 30, 2022 | -2,303.46% |
| Mar 31, 2022 | -1,875.06% |
| Dec 31, 2021 | -130.71% |
| Sep 30, 2021 | -8,709.07% |
| Jun 30, 2021 | -11,509.69% |